Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Neff

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Clinical Therapeutics|April 29, 2014
LDL-C levels in US patients at high cardiovascular risk receiving rosuvastatin monotherapyVeronica Ashton, Qiaoyi Zhang, Ning Jackie Zhang, et al.
American Heart Journal|July 3, 2013
Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United StatesMeredith C Foster, Andreea M Rawlings, Elizabeth Marrett, et al.
Vascular Health and Risk Management|November 23, 2013
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapyJoAnne M Foody, Peter P Toth, Joanne E Tomassini, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 20, 2019
Operationalizing a Data to Care Strategy in Michigan Through Cross-Agency CollaborationsKathryn E Macomber, Abigail Viall, Vishakha Ramakrishnan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 28, 2013
Potential effects of reclassifying CKD as a coronary heart disease risk equivalent in the US populationMeredith C Foster, Andreea M Rawlings, Elizabeth Marrett, et al.
Journal of Clinical Lipidology|March 6, 2012
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reductionPeter P Toth, Christie M Ballantyne, Michael H Davidson, et al.
Atherosclerosis|October 1, 2013
Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humansMichael H Davidson, Jason Voogt, Jayraz Luchoomun, et al.
Frontiers in Cardiovascular Medicine|January 23, 2023
Bayesian network analysis of panomic biological big data identifies the importance of triglyceride-rich LDL in atherosclerosis developmentSzilard Voros, Aruna T Bansal, Michael R Barnes, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Clinical Therapeutics|April 29, 2014
LDL-C levels in US patients at high cardiovascular risk receiving rosuvastatin monotherapyVeronica Ashton, Qiaoyi Zhang, Ning Jackie Zhang, et al.
American Heart Journal|July 3, 2013
Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United StatesMeredith C Foster, Andreea M Rawlings, Elizabeth Marrett, et al.
Vascular Health and Risk Management|November 23, 2013
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapyJoAnne M Foody, Peter P Toth, Joanne E Tomassini, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 20, 2019
Operationalizing a Data to Care Strategy in Michigan Through Cross-Agency CollaborationsKathryn E Macomber, Abigail Viall, Vishakha Ramakrishnan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 28, 2013
Potential effects of reclassifying CKD as a coronary heart disease risk equivalent in the US populationMeredith C Foster, Andreea M Rawlings, Elizabeth Marrett, et al.
Journal of Clinical Lipidology|March 6, 2012
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reductionPeter P Toth, Christie M Ballantyne, Michael H Davidson, et al.
Atherosclerosis|October 1, 2013
Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humansMichael H Davidson, Jason Voogt, Jayraz Luchoomun, et al.
Frontiers in Cardiovascular Medicine|January 23, 2023
Bayesian network analysis of panomic biological big data identifies the importance of triglyceride-rich LDL in atherosclerosis developmentSzilard Voros, Aruna T Bansal, Michael R Barnes, et al.
Pageof 3